Ipsen strengthens its Middle East presence with new Saudi Arabia office

 Ipsen, a leading French biopharma company, today announced the strategic opening of an office in Riyadh, marking a significant step for the company as it continues to expand its presence in the Middle East. The new location will support Ipsen’s vision and efforts to bring innovative therapies to patients, and serve unmet medical needs covering oncology, neuroscience, and rare diseases in Saudi Arabia and the region. It will also serve as a platform for the company to work closely with local partners to better understand the needs of the market.
Commenting on the opening, Mari Scheiffele, EVP & President Specialty Care International said: “The opening of the office highlights Ipsen’s vision of creating value by serving patients with high unmet medical needs across oncology, rare diseases and neuroscience.

It also aligns with Saudi Arabia’s Vision 2030, which aims to diversify the economy and increase the role of the private sector in driving growth. Ipsen’s investment in the country is a testament to the potential of the Saudi market and the company’s belief in the Kingdom’s ability to achieve its ambitious goals. We look forward to tapping into significant potential and further expand our footprint as we explore the unique growing opportunities the market can offer.”


Adel Alohali, Head of KSA at Ipsen said: “We are honored to count Ipsen as part of our rapidly growing healthcare industry. The company is known for delivering breakthrough solutions that improve the lives of patients and help healthcare professionals provide the best possible care. As the largest healthcare market in the region, Saudi Arabia’s burgeoning healthcare sector offers tremendous attractive opportunities. We are confident that Ipsen’s presence will be a valuable asset for our market and contribute to the health and well-being of our citizens, while also advancing the Kingdom’s vision in the sector.”

The official inauguration of Ipsen’s office in Riyadh was attended by Dr. Yaarob Aldugathier, Ministry of Investment International Office Director-France, MISA, Mr. Ludovic Pouille, Ambassador of France to Saudi Arabia, Matthieu Saverzeix, VP of MEAM, Khaled Elrefae GM of MEA and other senior executives from the company, as well as members of the medical community.

مقالات ذات صلة

زر الذهاب إلى الأعلى